An early feasibility study of the Nativis Voyager

Publication Title

CNS Oncol

Authors

Charles Cobbs, Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center, Seattle, WA 98122, USA.Follow
Edward McClay
J Paul Duic
L Burt Nabors
Donna Morgan Murray
Santosh Kesari, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute, Santa Monica, CA 90404, USA.Follow

Document Type

Article

Publication Date

12-14-2018

Keywords

clinical trials; medical device; novel therapy; recurrent GBM; ultra-low radiofrequency energy; brain tumor

Abstract

AIM: Evaluation of the Nativis Voyager

MATERIALS & METHODS: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE

RESULTS: Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported.

CONCLUSION: These data suggest that the Voyager is safe and feasible for the treatment of rGBM.

Area of Special Interest

Neurosciences (Brain & Spine)

Area of Special Interest

Cancer

Specialty/Research Institute

Neurosciences

Specialty/Research Institute

Oncology